在高危婴儿中发现围产期艾滋病病毒传播。

IF 2.2 4区 医学 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Journal of Public Health Management and Practice Pub Date : 2024-09-01 Epub Date: 2024-07-22 DOI:10.1097/PHH.0000000000001976
Thomas J O'Grady, Suzanne Kaufman, Amanda Stolz, Linda M Styer, Lisa Haskin, Prapitha Suresh, Nko L Ryman, Dipal Shah, Timothy J Sullivan, Lucia Torian, Charles Gonzalez, Monica M Parker, Carol-Ann Swain
{"title":"在高危婴儿中发现围产期艾滋病病毒传播。","authors":"Thomas J O'Grady, Suzanne Kaufman, Amanda Stolz, Linda M Styer, Lisa Haskin, Prapitha Suresh, Nko L Ryman, Dipal Shah, Timothy J Sullivan, Lucia Torian, Charles Gonzalez, Monica M Parker, Carol-Ann Swain","doi":"10.1097/PHH.0000000000001976","DOIUrl":null,"url":null,"abstract":"<p><p>The focus of this case study is the delayed diagnosis of a perinatal HIV transmission, which was identified when the infant reached 4 months of age, and the social conditions and structural determinants that contributed to the increased transmission risk. Despite adhering to the diagnostic testing protocols and neonatal antiretroviral (ARV) guidelines of the New York State Department of Health, this transmission still occurred. This transmission event prompted strategies to address criminalization of substance use during pregnancy and a reevaluation of the HIV testing and treatment protocols, including the timing of testing. Obtaining a diagnostic specimen at birth before initiating prophylactic or presumptive therapy, without causing delays in therapy, and incorporating HIV-1 DNA or RNA testing 2 to 6 weeks after discontinuing ARV therapy might have facilitated earlier detection and a quicker resumption of ARV therapy for this high-risk infant. Subsequently, the New York State HIV perinatal testing guidelines were updated. These changes included the recommendation to obtain a diagnostic specimen at birth before initiating ARV medications, whenever feasible, without causing delays in ARV initiation. Additionally, an extra virologic diagnostic test is recommended at 2 to 6 weeks after discontinuing ARVs for infants at high risk of perinatal HIV transmission, especially those with possible DNA or RNA suppression due to ARV prophylaxis or presumptive HIV therapy.</p>","PeriodicalId":47855,"journal":{"name":"Journal of Public Health Management and Practice","volume":"30 5","pages":"653-656"},"PeriodicalIF":2.2000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Late Identification of Perinatal Transmission of HIV in an Infant at High Risk.\",\"authors\":\"Thomas J O'Grady, Suzanne Kaufman, Amanda Stolz, Linda M Styer, Lisa Haskin, Prapitha Suresh, Nko L Ryman, Dipal Shah, Timothy J Sullivan, Lucia Torian, Charles Gonzalez, Monica M Parker, Carol-Ann Swain\",\"doi\":\"10.1097/PHH.0000000000001976\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The focus of this case study is the delayed diagnosis of a perinatal HIV transmission, which was identified when the infant reached 4 months of age, and the social conditions and structural determinants that contributed to the increased transmission risk. Despite adhering to the diagnostic testing protocols and neonatal antiretroviral (ARV) guidelines of the New York State Department of Health, this transmission still occurred. This transmission event prompted strategies to address criminalization of substance use during pregnancy and a reevaluation of the HIV testing and treatment protocols, including the timing of testing. Obtaining a diagnostic specimen at birth before initiating prophylactic or presumptive therapy, without causing delays in therapy, and incorporating HIV-1 DNA or RNA testing 2 to 6 weeks after discontinuing ARV therapy might have facilitated earlier detection and a quicker resumption of ARV therapy for this high-risk infant. Subsequently, the New York State HIV perinatal testing guidelines were updated. These changes included the recommendation to obtain a diagnostic specimen at birth before initiating ARV medications, whenever feasible, without causing delays in ARV initiation. Additionally, an extra virologic diagnostic test is recommended at 2 to 6 weeks after discontinuing ARVs for infants at high risk of perinatal HIV transmission, especially those with possible DNA or RNA suppression due to ARV prophylaxis or presumptive HIV therapy.</p>\",\"PeriodicalId\":47855,\"journal\":{\"name\":\"Journal of Public Health Management and Practice\",\"volume\":\"30 5\",\"pages\":\"653-656\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Public Health Management and Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/PHH.0000000000001976\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Public Health Management and Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PHH.0000000000001976","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

本案例研究的重点是围产期艾滋病毒传播的延迟诊断(在婴儿满 4 个月时才被发现),以及导致传播风险增加的社会条件和结构性决定因素。尽管遵守了纽约州卫生部的诊断检测规程和新生儿抗逆转录病毒(ARV)指南,这次传播仍然发生了。这一传播事件促使我们制定战略,解决孕期使用药物的刑事定罪问题,并重新评估艾滋病毒检测和治疗方案,包括检测时间。在开始预防性或假定性治疗前,在婴儿出生时获取诊断标本,同时不耽误治疗,并在停止抗逆转录病毒治疗 2-6 周后进行 HIV-1 DNA 或 RNA 检测,可能有助于更早地发现这一高风险婴儿,并更快地恢复抗逆转录病毒治疗。随后,纽约州对围产期 HIV 检测指南进行了更新。这些变化包括建议在可行的情况下,在婴儿出生时获得诊断标本,然后再开始接受抗逆转录病毒药物治疗,而不会造成抗逆转录病毒药物治疗的延误。此外,对于围产期 HIV 传播高风险婴儿,尤其是那些 DNA 或 RNA 可能因抗逆转录病毒药物预防或推定 HIV 治疗而受到抑制的婴儿,建议在停用抗逆转录病毒药物后 2-6 周进行一次额外的病毒学诊断检测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Late Identification of Perinatal Transmission of HIV in an Infant at High Risk.

The focus of this case study is the delayed diagnosis of a perinatal HIV transmission, which was identified when the infant reached 4 months of age, and the social conditions and structural determinants that contributed to the increased transmission risk. Despite adhering to the diagnostic testing protocols and neonatal antiretroviral (ARV) guidelines of the New York State Department of Health, this transmission still occurred. This transmission event prompted strategies to address criminalization of substance use during pregnancy and a reevaluation of the HIV testing and treatment protocols, including the timing of testing. Obtaining a diagnostic specimen at birth before initiating prophylactic or presumptive therapy, without causing delays in therapy, and incorporating HIV-1 DNA or RNA testing 2 to 6 weeks after discontinuing ARV therapy might have facilitated earlier detection and a quicker resumption of ARV therapy for this high-risk infant. Subsequently, the New York State HIV perinatal testing guidelines were updated. These changes included the recommendation to obtain a diagnostic specimen at birth before initiating ARV medications, whenever feasible, without causing delays in ARV initiation. Additionally, an extra virologic diagnostic test is recommended at 2 to 6 weeks after discontinuing ARVs for infants at high risk of perinatal HIV transmission, especially those with possible DNA or RNA suppression due to ARV prophylaxis or presumptive HIV therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Public Health Management and Practice
Journal of Public Health Management and Practice PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
3.40
自引率
9.10%
发文量
287
期刊介绍: Journal of Public Health Management and Practice publishes articles which focus on evidence based public health practice and research. The journal is a bi-monthly peer-reviewed publication guided by a multidisciplinary editorial board of administrators, practitioners and scientists. Journal of Public Health Management and Practice publishes in a wide range of population health topics including research to practice; emergency preparedness; bioterrorism; infectious disease surveillance; environmental health; community health assessment, chronic disease prevention and health promotion, and academic-practice linkages.
期刊最新文献
Perspectives on Public Health Department Accreditation: Lessons Learned From Ohio's Accreditation Mandate. When Disasters Cross State Borders: Pennsylvania's Public Health Response to the Norfolk Southern Train Derailment in East Palestine, Ohio. Perceptions of Criticality and Frequency of Tasks by the Public Health Workforce, 2022. Real-Time Dashboard for Identifying Overdose Touchpoints in Indiana. Assessing Facility Readiness to Provide Equitable Birthing Care in New York State: A Baseline Survey.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1